Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533280 | 0.72 | TDP1 (0.35) | NPSR1BACE1 | |
| SCHEMBL32670843 | 0.70 | CYP19A1 (0.40) | — | |
| SCHEMBL31590688 | 0.69 | EPHX1 (0.38) | — | |
| SCHEMBL27411953 | 0.66 | TAAR1 (0.40) | SLC6A2SLC6A3NPSR1SLC6A4BACE1 | |
| SCHEMBL296803 | 0.63 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4TAAR1CYP2D6 | |
| SCHEMBL13698273 | 0.63 | THRB (0.43) | SLC6A2SLC6A3SLC6A4BACE1 | |
| SCHEMBL28287364 | 0.62 | TAAR1 (0.43) | SLC6A2SLC6A3NPSR1SLC6A4BACE1 | |
| SCHEMBL657183 | 0.62 | SLC6A2 (0.44) | SLC6A2SLC6A3NPSR1SLC6A4BACE1 | |
| SCHEMBL7815009 | 0.61 | SLC6A2 (0.41) | SLC6A2SLC6A3SLC6A4CYP2D6KCNH2 | |
| SCHEMBL7770391 | 0.61 | ALDH1A1 (0.62) | SLC6A2SLC6A3SLC6A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2099806-B1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| EP-2200982-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-2167509-A1 | PIPERAZINE AND Ý1,4¨DIAZEPAN DERIVATIVES AS NK ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-7592345-B2 | Piperazine and [1,4]diazepan derivatives as NK antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-09-22 | — | — | US | disclosed |
| EP-2099806-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009033995-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
| US-7470684-B2 | Spiropiperidine derivatives as NK3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080312216-A1 | PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008151969-A1 | PIPERAZINE AND [1,4] DIAZEPAN DERIVATIVES AS NK ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-24 | — | — | US | disclosed |
| WO-2008081012-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312216-A1 | PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS | DRD3, KCND3, GRIN3A | SLC6A2 365/4885SLC6A3 15/4885NPSR1 5/4885 |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | SLC6A2 163/4885SLC6A3 14/4885NPSR1 20/4885 |
| US-20080176839-A1 | SPIROPIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | ADRB3, KCNK3, KCND3 | SLC6A2 177/4885SLC6A3 8/4885NPSR1 14/4885 |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | SLC6A2 163/4885SLC6A3 14/4885NPSR1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.